ctbp-1 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Research findings indicate a significant role for CTBP-1 in exploratory behavior and the regulation of dorsal SMD axonal morphology in C. elegans. PMID: 26480814
- Data confirms that CTBP-1 is involved in the regulation of lips-7 transcription, suggesting additional roles in the nervous system that contribute to the regulation of longevity. PMID: 25456848
- Findings suggest that CTBP-1 exerts control over lifespan likely through the regulation of lipid metabolism. PMID: 19164523
Q&A
Basic Research Questions
What validation methods confirm CtBP1 antibody specificity in experimental systems?
To ensure antibody specificity, employ a multi-modal validation approach:
-
Knockdown/knockout controls: Use siRNA or shRNA targeting CTBP1 to demonstrate reduced signal in Western blot (WB) or immunofluorescence (IF). For example, N2A cells with CtBP1 silencing showed diminished immunofluorescence signals .
-
Orthogonal techniques: Compare results across WB, immunoprecipitation (IP), and chromatin immunoprecipitation (ChIP). The VCU-developed CG14 antibody showed consistent performance in WB, IP, and ChIP assays .
-
Cross-reactivity checks: Verify absence of reactivity with paralogs (e.g., CtBP2) using cell lines expressing only CtBP2 .
How do researchers optimize CtBP1 antibody dilutions across applications?
Optimal dilutions vary by experimental context. A reference framework based on published data:
What are common cross-reactivity challenges with CtBP1 antibodies?
-
Paralog interference: Some commercial antibodies (e.g., Proteintech 10972-1-AP) show human/mouse reactivity but may cross-react with CtBP2 if epitopes overlap. The CG14 antibody avoids this by targeting CtBP1-specific regions .
-
Post-translational modifications: A faint 65 kDa band observed in human cell lines (vs. 48 kDa predicted) suggests modified isoforms; confirm via CtBP1 knockout controls .
Advanced Research Questions
How can researchers resolve discrepancies in reported CtBP1 molecular weights?
CtBP1 migrates variably in SDS-PAGE due to:
-
Post-translational modifications: Phosphorylation or SUMOylation alters mobility (e.g., 65 kDa band in HEK-293 cells ).
-
Proteolytic cleavage: Use fresh protease inhibitors and validate with full-length recombinant protein controls .
What experimental controls are critical for ChIP-seq using CtBP1 antibodies?
-
Negative controls: Non-specific IgG and primers targeting non-CtBP1-bound genomic regions (e.g., Gapdh) .
-
Positive controls: Known CtBP1-binding promoters (e.g., BRCA1 or Oprm1) .
-
Input normalization: Always include 1–2% input DNA for quantitative PCR normalization .
How should researchers interpret CtBP1 subcellular localization differences in cancer models?
CtBP1 exhibits context-dependent localization:
-
Nuclear localization: Associated with transcriptional repression (e.g., BRCA1 silencing in breast cancer) .
-
Cytoplasmic presence: Linked to metabolic regulation (e.g., NADH-dependent apoptosis in neurons) .
-
Methodological notes: Combine IF with compartment-specific markers (e.g., Lamin B1 for nucleus) and quantify localization using imaging software .
Data Contradiction Analysis
Why do studies report opposing roles for CtBP1 in prostate cancer?
-
Cell-type specificity: CtBP1 acts as a tumor suppressor in androgen receptor (AR)-positive cells but promotes proliferation in AR-negative lines .
-
Experimental design: Use isogenic cell lines with AR status modulation and correlate findings with clinical AR expression data .
How to address variability in CtBP1’s role in neuronal development vs. cancer?
-
Model systems: Compare iPSC-derived neurons (for neurodevelopmental defects ) vs. cancer cell lines (e.g., SKOV3 ovarian cancer ).
-
Pathway analysis: RNA-seq of CTBP1-mutant neurons showed downregulated synaptic genes , while cancer studies highlight upregulated EMT/metastasis genes .
